Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Earnings release
confidence 95%
filed 2026-09-24
EX-99.3
This exhibit is a press release announcing YYForce's unaudited financial results for the six months ended June 30, 2026. It discloses revenue of US$32.7 million (26.8% YoY growth), net loss of US$7.06 million (13.8% narrower YoY), and includes detailed operational metrics, management commentary, and forward-looking guidance. The document explicitly states "YYForce Issues First Half 2026 Financial Results" and includes condensed consolidated financial statements, making it a classic interim earnings release material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-24
Item 7.01
Kyverna announced positive one-year durability data from its registrational trials KYSA-8 (stiff person syndrome) and KYSA-6 (generalized myasthenia gravis) for miv-cel, with sustained clinical responses, favorable safety profiles, and a rolling BLA submission on track for Q4 2026. While this is clinical trial data disclosure rather than a traditional earnings release, it represents a material operational and strategic milestone for a late-stage clinical company—the data directly supports regulatory approval prospects and the company's pipeline advancement, which would affect a reasonable investor's assessment of the registrant's prospects.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-09-24
Item 1.01
On September 23, 2026, Jaguar Health completed a debt-for-equity exchange, issuing 547,898 shares of common stock to reduce the outstanding balance of a secured promissory note by $5.05 million. This restructuring materially affects the company's capital structure and shareholder equity.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-09-24
Item 1.01
Group 1 Automotive's subsidiary entered into a master credit agreement with Bank of America for a $190.3 million term loan secured by mortgages on real properties, with a 7-year maturity extending to September 2033. This material debt issuance represents a significant new direct financial obligation affecting the company's capital structure and financial flexibility.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-24
Item 7.01
Cullinan Therapeutics disclosed anticipated clinical trial milestones and data presentation timelines for Q4 2026 across its T cell engager pipeline (CLN-978, velinotamig, CLN-049), including specific dates for data releases and conference presentations.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 98%
filed 2026-09-24
EX-99.1
SES's Board of Directors approved and announced an interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) to be paid on October 15, 2026, reflecting the company's commitment to shareholder returns.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-24
EX-99.2
SES announced the appointment of Michel Scholer, Secretary General of the Luxembourg Government and Chief of Staff to the Prime Minister, to its Board of Directors effective immediately.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-24
Item 8.01
Aptevo announced progress in optimizing next-generation trispecific candidates for scalable manufacturing and expects to enter IND-enabling studies for lead candidate APVO451 in 1H2027. This is a material operational and development milestone for a clinical-stage biotech company—advancing a lead program toward human testing represents a significant strategic and value-creating event. While not a specific named category, this is clearly an operational/developmental milestone rather than financial, governance, or legal in nature.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-09-24
Item 5.02
Tarkan Maner, President and Chief Commercial Officer, is stepping down effective October 2, 2026. This is a clear departure of a named executive officer from a senior leadership position overseeing critical functions (sales, marketing, customer experience). While the filing mentions a potential transition arrangement, the principal disclosed action is the executive's departure from his role.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-09-24
Item 7.01
Medallion Bank announced the pricing of a public offering of 2,200,000 shares of Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series G, with an aggregate liquidation amount of $55 million. This constitutes creation of a new direct financial obligation through a preferred stock issuance, which is a form of debt-like capital raising. The filing explicitly discloses the pricing terms, dividend rates (9.00% fixed through July 1, 2030, then reset), and intended use of proceeds, including potential redemption of existing Series E Preferred Stock.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-24
Item 5.02
The filing discloses both the departure of Ann D. Janssen as Executive Vice President and Chief Financial Officer (effective December 31, 2026) and the appointment of Jeffrey W. Hibbard to succeed her in that role (effective January 1, 2027). While both events occur, the principal disclosed action centers on the appointment of a new CFO to a critical executive position. The appointment of Hibbard as the successor CFO is the forward-looking material event, making exec_appointment the most salient classification, though a departure also occurred.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-24
Item 7.01
Weyerhaeuser disclosed an accelerated growth strategy targeting $1.5 billion of incremental Adjusted EBITDA by 2030 (measured against a 2024 baseline) through multiple strategic initiatives across timberlands, wood products, and climate solutions, along with adjustments to its third-quarter 2026 outlook. The investor presentation outlines comprehensive operational and strategic plans that materially affect investor assessment of the company's future performance and capital allocation priorities.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-09-24
Item 1.01
CarMax Auto Funding LLC entered into an Underwriting Agreement on September 22, 2026 for the issuance of $600.64 million in aggregate principal amount of asset-backed notes across six classes (A-1, A-2, A-3, B, C, D, and E), backed by motor vehicle retail installment sale contracts. This constitutes a material securitization financing activity and creation of a new direct financial obligation.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
EQT Infrastructure sold approximately $104.4 million in unregistered Investor Shares across multiple share classes to third-party investors as of September 1, 2026, relying on Section 4(a)(2) and Regulations D and S exemptions. This is a classic dilutive private placement of equity securities. The filing explicitly discloses this under Item 3.02 (Unregistered Sales of Equity Securities), and the cumulative offering since inception ($1.008 billion) demonstrates material capital-raising activity that would affect investor assessment of ownership dilution and the company's financing strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
EQT Private Equity Company LLC disclosed an unregistered sale of approximately $28.1 million in equity shares (990,093 shares across multiple classes) to third-party investors as of September 1, 2026, relying on Section 4(a)(2) and Regulations D and S exemptions. This is a classic dilutive issuance of unregistered equity securities. The disclosure notes cumulative sales of approximately $861.1 million since inception on July 1, 2025, indicating a material ongoing capital-raising activity that would affect investor assessment of ownership dilution and the company's capital structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-24
Item 5.02
The filing discloses the election of Keli Walbert to the Board of Directors as a Class I director effective immediately, with appointment to the Audit Committee. While the disclosure includes compensatory arrangements (equity option grant and annual cash compensation), the principal disclosed action is the appointment of a new director to the Board and a Board committee, making exec_appointment the most salient classification. Board composition changes are material to investors.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-09-24
Item 1.01
TTM Technologies completed a $500 million private offering of 6.750% senior notes due 2034 on September 24, 2026, with proceeds earmarked for the acquisition of EDS Intermediate Holding, LLC, general corporate purposes, and related fees. The issuance creates a material direct financial obligation and materially affects the company's financial structure and leverage.
View raw filing on EDGAR →
8-K
Governance Other
confidence 72%
filed 2026-09-24
Item 3.03
The senior notes indenture imposes material restrictions on the Company's ability to declare or pay dividends and make distributions on capital stock, constraining shareholder capital allocation rights pursuant to the debt instrument's covenants.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-24
Item 7.01
The Board of Trustees declared a regular distribution on common shares with a gross per-share amount of $0.1600 across multiple share classes, payable on October 28, 2026.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-09-24
Item 8.01
The Fund disclosed its Net Asset Value per share as of August 31, 2026 ($22.32), aggregate NAV of $4.3 billion, portfolio fair value of $6.8 billion, outstanding debt of $2.6 billion, and leverage ratio of 0.58x, along with a status update on ongoing public and private share offerings totaling approximately $4.8 billion in consideration to date.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
North Haven Private Income Fund LLC completed an unregistered sale of approximately 432,819 Class S units for $7.73 million to accredited investors pursuant to subscription agreements, relying on Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-24
Item 7.01
The Fund declared a regular distribution of $0.1190 per unit and a special distribution of $0.0110 per unit, both payable on October 5, 2026 to unitholders of record as of September 30, 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
North Haven Private Income Fund A LLC completed an unregistered sale of approximately 135,464 Class I units for $2.6 million to accredited investors, relying on Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-09-24
Item 7.01
The Fund declared a regular distribution of $0.1376 per unit and a special distribution of $0.0246 per unit, both payable on October 5, 2026 to unitholders of record as of September 30, 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-09-24
Item 1.01
Akamai entered into material definitive agreements with Anthropic (Project Plans 2 and 3 under an MSA) valued at approximately $11.6 billion over seven years with potential expansion to ~$20 billion, coupled with issuance of a warrant for up to 7.7 million shares (5% of outstanding common stock on an as-converted basis). The filing explicitly states the Anthropic MSA is 'no longer immaterial in amount or significance to the Company,' and the scale, strategic importance, warrant dilution, and capital expenditure impact ($5.5 billion capex, $1.7 billion in 2026) make this a material commercial arrangement affecting the registrant's financial position and growth trajectory.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-24
Item 5.07
This is a clear disclosure of shareholder vote results from a Special Meeting held on September 24, 2026. The filing reports the outcome of Proposal No. 1 regarding approval of a reverse stock split (1-for-5 to 1-for-15 ratio) at the Company's discretion, with 102.5 million votes in favor, 9.3 million against, and 191,821 abstentions. The reverse stock split is material to investors as it affects share structure and is typically undertaken to address delisting risk or improve stock price perception.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 89%
filed 2026-09-24
Item 1.01
Marriott entered into a Seventh Amended and Restated Credit Agreement that increases aggregate commitments from $4.50 billion to $5.00 billion, extends the maturity date to September 23, 2031, and adjusts interest rate margins and facility fees.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 90%
filed 2026-09-24
Item 1.01
Nissan Auto Receivables 2026-B Owner Trust entered into an Underwriting Agreement for the issuance and sale of asset-backed notes with an aggregate principal balance of $1,285,670,000 across multiple classes (A-1 through C), backed by retail installment sales contracts. The securitization transaction closed with the transfer of receivables and issuance of notes under standard securitization agreements including a Purchase Agreement, Sale and Servicing Agreement, Indenture, and Administration Agreement.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-09-24
Item 8.01
The registrant has filed a prospectus describing the issuance of approximately $1.286 billion in aggregate principal amount of asset-backed notes across seven classes (A-1, A-2a, A-2b, A-3, A-4, B, and C) by Nissan Auto Receivables 2026-B Owner Trust. This constitutes creation of new direct financial obligations through debt issuance, fitting the debt_issuance category. The materiality is clear given the substantial aggregate principal amount and the prospectus filing requirement.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-24
Wells Fargo issued $6 billion in Medium-Term Notes, Series Y on September 24, 2026: $2.5 billion in Senior Redeemable Fixed-to-Floating Rate Notes due 2030 and $3.5 billion due 2037. This is a material creation of direct financial obligations disclosed under Item 9.01 (Financial Statements and Exhibits), with the forms of the notes and legal opinion filed as exhibits—a standard debt issuance disclosure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-24
Item 3.01
The filing discloses that Beasley Broadcast Group is no longer compliant with Nasdaq Rule 5605(c)(2)(A) following the death of director Peter A. Bordes, Jr., which reduced the Audit Committee below the required three independent members. The Company has notified Nasdaq and is relying on a cure period expiring September 19, 2027 or at the next annual stockholder meeting to restore compliance. This is a material failure to satisfy a continued listing rule that directly triggers Item 3.01 disclosure requirements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-09-24
Item 7.01
Stifel issued a press release on September 24, 2026, disclosing selected operating results for August 31, 2026, including key performance metrics such as total client assets ($587.6B), fee-based client assets ($244.4B), treasury deposits, and bank loans. The CEO commentary provides forward guidance on Q3 2026 net revenue expectations. Although labeled Item 7.01, the filing explicitly references Item 2.02 and furnishes a press release with financial operating data and management commentary, which is the hallmark of an earnings or results disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-09-24
Item 8.01
This Item 8.01 disclosure reports the consummation of Haymaker Acquisition Corp V's IPO on September 18, 2026, generating $287.5 million in gross proceeds from the sale of 28.75 million units at $10.00 per unit, plus $8 million from concurrent private placement warrant sales. While the filing is clearly material to investors (establishing the company's capital base and trust account), it does not fit neatly into the standard event taxonomy. The IPO itself is a capital-raising event, but the taxonomy lacks a dedicated "IPO" or "initial_public_offering" category. The disclosure is not an earnings release, M&A activity, debt issuance, or dilutive equity issuance in the traditional sense (this is a SPAC formation, not a secondary offering by an operating company). The event is financial in nature but does not match specific financial event types. "Other_material" is appropriate here as the domain is clear (financial/capital) but no specific type fits the SPAC IPO structure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-24
Item 2.03
USA Compression Partners issued $600 million in aggregate principal amount of 6.750% senior notes due 2035 pursuant to an Indenture dated September 18, 2026. The proceeds were used to repay credit agreement borrowings, representing a material creation of direct financial obligation.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
LGAM Private Credit LLC sold approximately 55,206 Common Units for $1.1 million (~$19.46 per unit) pursuant to subscription agreements, relying on Regulation S and other exemptions from Securities Act registration.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-09-24
Item 7.01
The company declared a regular distribution to unitholders of $0.1378 per unit, payable October 5, 2026.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-09-24
Item 4.01
The filing discloses a change in the registrant's independent auditor under Item 4.01. Baker Tilly, the auditor since 2020, was dismissed by the Audit Committee on September 18, 2026, and Ernst & Young LLP was appointed as the successor auditor for the fiscal year ending June 30, 2027. This is a direct and unambiguous auditor change event, material to investors as it affects the firm responsible for attesting to financial statements.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-09-24
Item 2.03
The filing discloses a draw of $650,000 under an existing revolving credit facility established on April 21, 2026 with Parkview Holdings One LLC. This represents the creation of a direct financial obligation under Item 2.03, and while the underlying facility was previously disclosed, the incremental borrowing on September 21, 2026 constitutes a material debt issuance event that increases the company's direct financial obligations.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-09-24
Item 5.02
Scott A. Genereux, Chief Revenue Officer of Rockwell Automation, notified the company on September 21, 2026 of his decision to retire effective December 31, 2026. He will cease serving as CRO effective September 30, 2026, remaining as Senior Vice President through year-end. This is a clear executive departure of a named officer in a material C-suite role (CRO), making it material to investors assessing the company's leadership and revenue strategy.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-24
Item 8.01
EIDP issued $700 million of senior notes due 2036 bearing 6.000% interest in a private offering. This is a material creation of a direct financial obligation. The notes were issued pursuant to an indenture and include customary events of default and redemption provisions, including a special mandatory redemption tied to completion of the Corteva separation. The disclosure of a substantial debt issuance in Item 8.01 (Other Events) is a core debt_issuance event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-24
Item 8.01
Acadia announced Phase 2 topline results from the RADIANT clinical trial of remlifanserin for Alzheimer's disease psychosis. The trial narrowly missed its primary endpoint (p=0.0603) but achieved significance on a key secondary endpoint (p=0.0077); the company plans to continue Phase 3 development with protocol amendments including removal of the 30 mg dosage arm.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-24
Item 1.01
Atlas Energy Solutions entered into a material definitive agreement with Wyoming Machinery Company for approximately $340.5 million in balance-of-plant equipment procurement for a power generation project, representing a significant operational and capital commitment affecting the company's strategic direction and financial obligations.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-24
Item 8.01
Atlas Energy Solutions entered into a Generator Purchase Agreement with WMC for approximately 328 MWs of power generation equipment valued at $273.0 million, payable through January 2028 with delivery through February 2028, satisfying a portion of its obligation under a previously announced Global Framework Agreement with Caterpillar.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-24
Item 5.02
Talos Energy appointed Barbara J. Faulkenberry, Major General U.S. Air Force (Retired), as a director effective October 1, 2026, expanding the Board to seven members. General Faulkenberry brings 32 years of military leadership experience and prior public company board service at Callon Petroleum, Target Hospitality, and USA Truck.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-09-24
Item 1.01
PGIM Private Credit Fund's special purpose vehicle entered into Amendment No. 1 to a Loan and Servicing Agreement, increasing the facility amount from $100 million to $200 million, amending the applicable margin, and revising concentration and reporting requirements. This material modification doubles the facility size and represents a significant expansion of the Fund's direct financial obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-24
Item 3.02
Jaguar Health completed a debt-for-equity exchange on September 23, 2026, issuing 729,989 shares of common stock (including 182,091 shares under Item 1.01 and 547,898 shares under Item 1.02) to reduce and fully cancel approximately $6.73M in secured promissory note obligations. The transaction materially restructures the company's capital structure through equity dilution.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-09-24
Item 5.02
Eli Berkovitch, the principal accounting officer and Vice President, Chief Accounting Officer and Controller, informed the Company of his intention to resign effective October 23, 2026. While the filing also mentions Dylan Smith assuming interim principal accounting officer duties, the principal disclosed action is Berkovitch's departure after eleven-and-a-half years of service. The departure of a principal accounting officer is material to investors assessing the registrant's financial reporting and internal controls.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-24
EX-99.1
This press release announces the publication of three U.S. patent applications covering novel combinations of LSD, ketamine, and ibogaine with NeuroThera's PEA technology, developed through an ongoing collaboration with Clearmind Medicine. The disclosure highlights expansion of the intellectual property portfolio for potential therapeutic applications in mental health and substance use disorders. This is a material operational/strategic milestone—the maturation and enhancement of a core asset (patent portfolio) supporting the company's drug development programs—but does not fit the specific event categories of M&A, earnings, executive changes, or other named types. It represents progress in the company's clinical-stage pharmaceutical development strategy.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-09-24
The 6-K discloses completion of three material acquisitions: (1) Qingdao Xingongguan (100% equity control via VIE for US$5.8M, settled via issuance of 15.9B Class A shares), (2) Zhaodong Guohe assets (US$21.2M, settled via 57.9B Class A shares), and (3) First-Phase Qingdao Quanao (33.33% equity stake for US$25M, settled via 72.8B Class A shares). These are material acquisitions and dispositions under Item 1.01/2.01, collectively involving ~US$52M in consideration and massive dilutive share issuances (146.6B Class A shares / 24.4M ADSs), materially affecting shareholder equity and ownership structure.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-09-24
EX-99.1
This is a press release announcing Pasqal's first half 2026 financial results, dated September 24, 2026. It discloses revenue of €4.9 million (14% YoY growth), operating loss of €59.2 million, cash position of €110.8 million as of June 30, 2026, and includes condensed consolidated financial statements (balance sheet, P&L, and cash flows). The document explicitly states "Pasqal Reports First Half 2026 Financial Results" and includes detailed financial highlights and business metrics. This is a discrete earnings announcement, not a periodic financial report filing itself, and is material to investors assessing the registrant's financial performance and operational progress.
View raw filing on EDGAR →